Datavault AI (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion is significant because it moves blockchain-based data management from a narrow pharmaceutical focus into broader healthcare applications, potentially giving patients more control over their own health data. The integration of Datavault AI’s technology—including its DataMEDS platform—could enable new revenue models for patients through data monetization and tokenization. Additionally, the deal aligns with trends in decentralized health data management, where patients can decide who accesses their medical records and potentially earn from that access.
The announcement also highlights the growing intersection of AI, blockchain and healthcare. Datavault AI’s Data Science division leverages Web 3.0 and high-performance computing for experiential data perception, valuation and secure monetization. The company’s platform serves multiple industries including healthcare, and its Information Data Exchange enables Digital Twins and secure attachment of physical objects to immutable metadata.
By targeting the global health and wellness market, which is expanding rapidly due to aging populations and increasing focus on preventive care, Datavault AI positions itself to capitalize on the growing demand for patient-centric data solutions. The deal also provides Datavault AI with a significant equity stake in DataMEDS, aligning incentives for long-term collaboration.
Investors and industry observers will watch how this partnership develops, particularly regarding regulatory compliance and adoption by healthcare providers. The success of patient-controlled data models depends on trust, security and interoperability with existing health IT systems. Datavault AI’s technology, including its acoustic sciences division featuring WiSA and ADIO technologies, may also find applications in healthcare settings such as telemedicine and remote monitoring.
